Study guide

RSV Pathogenesis, Supportive Management, Oxygen/High-Flow Criteria, and Futility of Bronchodilators/Steroids

EBP-EAP Examination in Paediatrics Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Governance, Ethics & Child Safeguarding

EBP-EAP Format, Delivery, Scoring, and Clinical Vignette Strategy Paediatric Ethics, Consent/Assent, Gillick Competence, and Patient Safety Child Protection, Physical/Emotional Abuse, Neglect, and Non-Accidental Injury (NAI)

2 Chapter 2: Neonatal Transition, Resuscitation & Prematurity

Delivery Room Care, Apgar Scoring, and Neonatal Resuscitation Algorithm Respiratory Distress Syndrome (RDS), Surfactant Therapy, and Bronchopulmonary Dysplasia Perinatal Asphyxia, HIE Sarnat Staging, and Therapeutic Hypothermia Protocol

3 Chapter 3: Neonatal Morbidities, Jaundice & Congenital Infections

Unconjugated vs Conjugated Hyperbilirubinemia, Phototherapy Thresholds, and Exchange Transfusion Early- vs Late-Onset Sepsis, Group B Streptococcus, and Congenital TORCH Infections NEC Diagnosis/Bell Staging, Neonatal Hypoglycaemia, and Newborn Bloodspot Screening

4 Chapter 4: Acute Paediatric Emergencies & Critical Care

EPLS/PALS Structured Approach, Types of Shock, and Weight-Based Fluid Boluses Clinical Diagnostic Criteria, Intramuscular Adrenaline Dosing, and Refractory Anaphylaxis 5-Minute Time-Critical Anticonvulsant Protocol and Status Epilepticus Care Common Toxidromes (Paracetamol, Iron, Caustics, Button Batteries) and Decontamination

5 Chapter 5: Paediatric Respiratory Medicine

Stridor Differential, Croup (Westley Score & Dexamethasone), and Epiglottitis RSV Pathogenesis, Supportive Management, Oxygen/High-Flow Criteria, and Futility of Bronchodilators/Steroids European/BTS Guidelines on Chronic Stepwise Control and Acute Severe Exacerbation Management Community-Acquired Pneumonia Etiology, Parapneumonic Effusion/Empyema, and Cystic Fibrosis Pulmonary Exacerbations

6 Chapter 6: Paediatric Cardiology

Acyanotic vs Cyanotic Congenital Heart Disease: Ductal Patency, Shunt Lesions, and Emergency Stabilization Paediatric Murmurs and Arrhythmias: Innocent vs Pathological Murmurs, SVT, and Resuscitation Protocols Acquired Heart Disease: Kawasaki Disease, Coronary Aneurysm Prevention, and Acute Rheumatic Fever

7 Chapter 7: Paediatric Gastroenterology, Hepatology & Nutrition

Dehydration Severity Assessment, Oral Rehydration Therapy (ORT), and Intravenous Fluid Protocols ESPGHAN Coeliac Diagnostic Criteria (Biopsy-Sparing Pathway) and Paediatric Crohn's/Ulcerative Colitis Breastfeeding, Formula Selection, Cow's Milk Protein Allergy (CMPA), GERD vs GOR, and Faltering Growth Prolonged Neonatal Jaundice Workup, Biliary Atresia Red Flags, and Acute Hepatitis/Liver Failure

8 Chapter 8: Paediatric Nephrology, Fluids & Electrolyte Balance

Paediatric UTI Diagnosis, Imaging Criteria (Ultrasound/DMSA/MCUG), and Vesicoureteral Reflux Minimal Change Nephrotic Syndrome (Steroid Regimen & Complications) vs Acute Post-Infectious Glomerulonephritis Paediatric AKI (pRIFLE/KDIGO), Haemolytic Uraemic Syndrome (HUS), and Hyperkalaemia/Dysnatraemia Management

9 Chapter 9: Paediatric Endocrinology & Inborn Errors of Metabolism

Paediatric DKA Protocol (ISPAD/European Fluid & Insulin Guidelines, Cerebral Oedema Prevention) and T1DM Maintenance Congenital Hypothyroidism Screening & Levothyroxine, Congenital Adrenal Hyperplasia (21-Hydroxylase Deficiency), and Adrenal Crisis Short Stature Workup, Precocious vs Delayed Puberty, and Approach to Suspected Inborn Errors of Metabolism (IEM)

10 Chapter 10: Paediatric Neurology, Neurodevelopment & Mental Health

Simple vs Complex Febrile Seizures, Childhood Epilepsy Syndromes (Absence, Infantile Spasms, Benign Rolandic), and Antiseizure Medications Red Flags for Raised Intracranial Pressure (ICP), Brain Tumours, Migraine vs Tension Headache Acute Bacterial Meningitis (LP Contraindications, Ceftriaxone, Dexamethasone) and Viral Encephalitis (Aciclovir) Developmental Milestones (Gross Motor, Fine Motor/Vision, Speech/Language, Social), Autism Spectrum, ADHD, and Cerebral Palsy

11 Chapter 11: Paediatric Haematology & Oncology

Microcytic Anaemia (Iron Deficiency vs Thalassaemia Trait/Mentzer Index), Haemolytic Anaemias (Spherocytosis, G6PD) Sickle Cell Crises (Vaso-occlusive, Acute Chest Syndrome, Stroke Prevention), Immune Thrombocytopenia (ITP), and Haemophilia A/B Acute Lymphoblastic Leukaemia (ALL), Neuroblastoma, Wilms Tumour, and Management of Febrile Neutropenia

12 Chapter 12: Paediatric Infectious Diseases, Immunology & Allergy

Common Childhood Exanthems: Clinical Morphology, Timelines, Complications, and Management Paediatric Tuberculosis, Sepsis Six in Children, and Acute Osteoarticular Infections Pediatric Allergy, Atopic Eczema, Food Hypersensitivity, and Desensitization Primary Immunodeficiencies, Warning Signs, Live Vaccine Contraindications, and European Immunisation Schedules

13 Chapter 13: Paediatric Musculoskeletal, Dermatology & Surgical Conditions

The Limping Child, Septic Arthritis vs Transient Synovitis, and Juvenile Idiopathic Arthritis Henoch-Schönlein Purpura, Kawasaki Disease vs MIS-C, Infantile Haemangiomas, and Common Pediatric Eruptions Acute Appendicitis, Intussusception, Pyloric Stenosis, Testicular Torsion, and Incarcerated Hernia

14 Chapter 14: Research Methods, Biostatistics & Evidence-Based Paediatrics

Study Designs, Causality, Bias, and Epidemiological Measures in Paediatrics Diagnostic Test Accuracy, Statistical Inference, and Hypothesis Testing Systematic Reviews, Meta-Analysis, Decision Analysis, and Paediatric Research Ethics

15 Chapter 15: Paediatric Ophthalmology & ENT Disorders

Paediatric Vision Assessment, Refractive Disorders, Strabismus, and Leukocoria Ocular Emergencies, Orbital Infections, ROP, and Systemic Manifestations Paediatric Otolaryngology: Otitis Media, Hearing Impairment, and Upper Airway Conditions

16 Chapter 16: Paediatric Sports Medicine & Musculoskeletal Health

Skeletal Maturity, Physeal Injuries, Apophysitis, and Overuse Syndromes Paediatric Sports Concussion, Second Impact Syndrome, and Return-to-Play Protocols Pre-Participation Screening, Physical Activity Guidelines, and Chronic Disease Clearance

17 Chapter 17: Adolescent Medicine & Healthcare Transition

Biopsychosocial Development, Pubertal Staging, and Adolescent Communication Adolescent Confidentiality, Risk Behaviours, Reproductive Health, and Eating Disorders Chronic Illness in Adolescence and Structured Healthcare Transition

18 Chapter 18: Paediatric Genetics, Dysmorphology & Clinical Genomics

Patterns of Inheritance, Non-Mendelian Mechanisms, and Pedigree Construction Clinical Dysmorphology, Chromosomal Aneuploidies, and Microdeletion Syndromes Genetic Testing Technologies, Prenatal Diagnosis, and Genetic Counselling Ethics

19 Chapter 19: Paediatric Mental Health, Behaviour & Community Medicine

Cognitive Development, Attachment, Screening, and Common Emotional Disorders Regulatory Disorders, Neurodevelopmental Behavioural Conditions, and Psychosomatic Illness Community Child Healthcare Structures, Disability Coordination, and Child Advocacy

RSV Pathogenesis, Supportive Management, Oxygen/High-Flow Criteria, and Futility of Bronchodilators/Steroids

Key Takeaways Explain This Topic AI

Acute bronchiolitis is driven by viral cytopathic necrosis of terminal bronchiolar epithelium and dense peribronchial lymphocytic infiltration, producing airway obstruction through luminal mucus plugs and sloughed cellular debris rather than smooth muscle bronchospasm.

The natural history of bronchiolitis peaks clinically between days 3 and 5 of illness, with clinical deterioration characterized by increased work of breathing, tachypnea, feeding fatigue, and fine end-inspiratory crackles on auscultation.

Do not routinely use salbutamol, corticosteroids, nebulized adrenaline, antibiotics or chest physiotherapy for uncomplicated bronchiolitis. Treat suspected concurrent bacterial infection when indicated; relevant secretion-clearance comorbidities may warrant physiotherapy assessment. Supportive care remains central.

Supportive management forms the therapeutic bedrock: fractionated enteral or nasogastric feeds, isotonic IV fluids when enteral hydration is unsuitable, with maintenance volume adjusted for hydration and non-osmotic ADH-related fluid retention, and oxygen for persistent SpO2 <90% from 6 weeks, or <92% below 6 weeks or with an underlying health condition (NICE).

HFNC at 1–2 L/kg/min can reduce work of breathing and treatment escalation after low-flow oxygen fails. It provides variable positive pressure and dead-space washout; a reduction in intubation has not been established. Monitor closely and escalate promptly to CPAP or invasive ventilation when indicated.

Last updated: November 2026

Respiratory Syncytial Virus (RSV) Virology and Bronchiolar Histopathology

Acute bronchiolitis is the single most common lower respiratory tract infection of infancy and the leading cause of pediatric hospital admissions worldwide. It is characterized by acute inflammation, edema, and epithelial necrosis of the smallest conducting airways (bronchioles <1 mm in internal diameter).

Viral Etiology and Epidemiology

Respiratory Syncytial Virus (RSV): An enveloped, negative-sense, single-stranded RNA virus of the Pneumoviridae family, RSV accounts for 60% to 80% of all clinical bronchiolitis presentations. RSV expresses two major surface glycoproteins: the G glycoprotein (which mediates viral attachment to respiratory ciliated cells) and the F glycoprotein (fusion protein, which mediates viral entry into host cells and syncytia formation by fusing adjacent infected cells).

Other Viral Pathogens: Human Rhinovirus (HRV, specifically HRV-C, which is strongly associated with recurrent wheezing and later childhood asthma), Human Metapneumovirus (hMPV), Parainfluenza viruses, Bocavirus, Influenza, and Coronaviruses.

Epidemiology: Exhibits a pronounced seasonal epidemic pattern throughout Europe, typically running from October/November to March/April , with a seasonal peak in December and January. Nearly 100% of children are infected with RSV by 2 years of age , with approximately 2% to 3% of all infants requiring hospital admission during their first winter.

Peak Age Incidence: Bronchiolitis predominantly affects infants younger than 12 months, with a peak incidence and highest severity occurring between 2 and 6 months of age , coinciding with the physiological nadir of transplacentally acquired maternal neutralizing antibodies.

Histopathology and Pathomechanics

Epithelial Inoculation and Cytolysis: Viral replication initiates in the nasopharyngeal mucosa and spreads down the respiratory tree via cell-to-cell transfer. RSV directly infects ciliated bronchiolar epithelial cells, triggering extensive cellular necrosis, apoptosis, and loss of ciliary function .

Peribronchial Inflammation: A dense mononuclear cell infiltrate (predominantly CD8+ T lymphocytes, macrophages, and neutrophils) invades the peribronchial and submucosal tissue, causing prominent submucosal edema .

Luminal Occlusion: The combination of sloughed necrotic epithelial cells, hypersecreted viscous mucus, fibrin, and cellular debris forms dense intraluminal plugs. Because infant bronchioles lack collateral ventilation (pores of Kohn and canals of Lambert are rudimentary until 6–8 years of age), this debris causes widespread, patchy airway occlusion.

Ventilation-Perfusion (V/Q) Mismatch:

Partial Occlusion: Creates a ball-valve obstruction, allowing inspiratory gas entry but trapping gas during expiration, producing marked dynamic hyperinflation and alveolar distension .

Complete Occlusion: Trapped distal gas is rapidly absorbed into the pulmonary capillary blood, causing subsegmental and patchy resorption atelectasis .

Blood perfusing non-ventilated, atelectatic alveoli results in profound intrapulmonary right-to-left shunting, generating significant ventilation-perfusion mismatch and arterial hypoxemia .

Note

Bronchiolar obstruction in infant bronchiolitis is predominantly mechanical (cellular debris, mucus plugs, and submucosal edema). Infant bronchiolar smooth muscle is structurally immature, sparsely distributed, and possesses low beta-2 adrenergic receptor coupling. Consequently, smooth muscle bronchospasm plays virtually no role in the pathogenesis of acute bronchiolitis.

  • Clinical Progression, Staging, and High-Risk Cohorts
  • The Natural History and Clinical Course

The clinical trajectory of acute viral bronchiolitis follows a predictable timeline that is critical for clinical decision-making and parental counseling: [Day 1 - 3: Upper Respiratory Prodrome]

  • Mild coryza, clear rhinorrhea, sneezing, low-grade fever (<38.5°C)
  • |
  • v
  • [Day 3 - 5: Lower Respiratory Tract Peak Severity]
  • Tachypnoea (RR 60-80/min), subcostal/intercostal retractions, nasal flaring
  • Auscultation: Fine end-inspiratory crackles + high-pitched expiratory wheeze
  • Feeding difficulties (<50% normal volume) due to tachypnoea-swallow mismatch
  • |
  • v
  • [Day 6 - 10+: Gradual Recovery Phase]
  • Work of breathing improves, appetite returns
  • Cough frequently persists for 2 to 3 weeks (post-viral airway clearance)
  • High-Risk Cohorts for Severe Disease and PICU Admission

Certain pediatric populations possess reduced physiological pulmonary reserve and an immature immunological response, placing them at heightened risk for life-threatening respiratory failure, severe apnoea, and intensive care admission:

High-Risk Patient Group Underlying Pathophysiological Mechanism Clinical Risk

Prematurity (<35 weeks gestation) Narrow baseline airway caliber, reduced alveolar surface area, blunted central chemoreceptor respiratory drive Increased risk of severe disease and PICU admission; susceptible to apnoea

Young Chronological Age (<6–8 weeks) Obligate nasal breathers, weak thoracic wall musculature, rapid diaphragmatic fatigue Severe apnoea, rapid exhaustion, acute respiratory acidosis

Hemodynamically Significant Congenital Heart Disease (CHD) Baseline pulmonary venous hypertension, left-to-right shunting, preexisting interstitial pulmonary edema Acute pulmonary hypertension crisis, intractable pulmonary edema, high mortality

Chronic Lung Disease of Prematurity (BPD) Arrested alveolarization, structural airway fibrosis, blunted gas diffusion capacity Severe hypercapnic respiratory failure requiring invasive mechanical ventilation

Neuromuscular Disorders Intercostal muscle weakness, impaired cough reflex, inability to clear secretions Mucus plugging, massive lobar collapse, secondary bacterial infection

Immunodeficiency Inability to restrict viral replication, persistent viral shedding for months Extensive necrotizing bronchiolitis, viral pneumonia

Evidence-Based Supportive Management Protocols

Because no targeted antiviral therapy exists for general clinical use in bronchiolitis, high-quality supportive care directed at fluid balance, nutrition, and oxygenation remains the foundational standard of medical management.

Fluid and Nutrition Management

Infants with bronchiolitis may struggle to coordinate feeding and breathing, particularly when tachypneic or distressed. Assess alertness, work of breathing, swallowing, intake and hydration together; respiratory rate alone does not determine feeding safety .

Oral Feeding: Support breastfeeding or smaller, frequent feeds when the infant can feed safely. Reassess if feeding increases distress or causes choking, fatigue or inadequate intake.

Enteral Tube Feeding (Nasogastric / Orogastric): Use NG/OG fluids when oral intake is inadequate, often below 50–75% of usual intake with clinical concern. Enteral hydration is generally preferred when tolerated. The major randomized trial found no significant difference in hospital stay between NG and IV hydration; NG insertion was more often successful on the first attempt.

Intravenous Hydration: Use isotonic IV fluids when enteral fluids are not tolerated or the infant has impending respiratory failure. Severe distress, recurrent apnoea or exhaustion requires urgent senior assessment of both respiratory support and feeding route.

Warning

SIADH AND HYPONATREMIA IN ACUTE BRONCHIOLITIS: Severe lower respiratory tract infections stimulate the non-osmotic release of antidiuretic hormone (ADH / vasopressin) , triggered by intrathoracic negative pressure and inflammatory cytokine release.

Infusing hypotonic fluids (e.g., 0.18% or 0.45% saline) carries a high risk of fatal hyponatremic encephalopathy and seizures .

Always prescribe isotonic crystalloid solutions (e.g., 0.9% Normal Saline with 5% Dextrose, or Plasmalyte 148 with 5% Dextrose).

Individualize fluid volume : consider reducing maintenance, for example to 50–80%, when non-osmotic ADH secretion risks water retention. Assess dehydration and ongoing losses separately, monitor weight, urine output and electrolytes, and adjust to avoid both overload and underhydration.

Oxygen Therapy and Monitoring

Use the locally applicable oxygen protocol. NICE uses the following age- and risk-specific thresholds:

Supplemental Oxygen Threshold: Give oxygen for persistent SpO2 <90% at age ≥6 weeks , or <92% below 6 weeks or at any age with an underlying health condition . Assess severe distress, apnoea or exhaustion urgently regardless of SpO2; oxygen does not replace ventilatory support.

Delivery: Delivered via low-flow humidified nasal cannulae (0.5 to 2 L/min) or humidified face mask.

Discontinuation: Trial withdrawal as the infant improves and maintains the age/risk-appropriate saturation in room air. Before discharge, document over 90% , or over 92% for the higher-risk group , for 4 hours including sleep, alongside clinical stability and adequate intake.

Continuous vs Spot-Check Oximetry: Continuous pulse oximetry in clinically stable, non-oxygen-dependent infants artificially prolongs hospital length of stay due to normal physiological transient desaturations. Oximetry should transition to intermittent spot checks as the infant stabilizes.

Escalating Respiratory Support: High-Flow Nasal Cannula (HFNC)

Heated Humidified High-Flow Nasal Cannula (HFNC) therapy has revolutionized the management of moderate-to-severe bronchiolitis failing conventional low-flow oxygen.

Mechanisms of Action

HFNC delivers blended air and oxygen heated to physiological body temperature (37°C) and 100% relative humidity at high flow rates:

Pharyngeal Dead Space Washout: Flushes the anatomical nasopharynx between breaths, washing out expired CO2-rich gas and creating an upper airway reservoir of fresh gas, substantially reducing rebreathing and metabolic ventilatory work.

Dynamic Positive Airway Pressure (PEEP): Generates a low-level, flow-dependent positive end-expiratory pressure (approximately 2 to 4 cmH2O at recommended flows when the mouth is closed). This counteracts intrinsic airway collapse, recruits atelectatic alveoli, and increases functional residual capacity (FRC).

Overcoming Inspiratory Resistance: Matches or exceeds the infant's peak inspiratory flow demand, dramatically diminishing the muscular work of breathing.

Mucociliary Preservation: Physiological heating and complete humidification prevent airway epithelial drying, promote ciliary clearance of viscous secretions, and prevent bronchoconstriction induced by cold, dry gas.

Clinical Implementation Protocol

Flow Rate: Initiated at 2.0 L/kg/min for the first 10 kg of body weight (typically 1.5 to 2.0 L/kg/min). For children >10 kg, add 0.5 L/kg/min for each additional kilogram.

FiO2 Titration: Titrate oxygen to the age/risk-appropriate saturation target using the minimum effective FiO2. A rising requirement, particularly >0.50, or persistent distress requires urgent senior/PICU review rather than simply increasing oxygen.

Prong Sizing: Nasal prongs must occlude no more than 50% of the internal nares diameter to ensure an adequate leak around the prongs, preventing unchecked barotrauma and subcutaneous air leaks.

Clinical Response: A positive clinical response (defined by a significant reduction in respiratory rate by >15–20% and marked reduction in work of breathing) should be evident within 60 to 90 minutes . Failure to improve mandates urgent escalation to Continuous Positive Airway Pressure (CPAP) or PICU transfer.

The "Choosing Wisely" Mandate: Definitive Evidence of Futility

Randomized trials and evidence-based guidelines support supportive care rather than routine drug treatment for uncomplicated bronchiolitis. A recommendation against routine use is not an absolute contraindication when a separate clinical indication exists. The table summarizes routine bronchiolitis care:

Interventions Evidence and Rationale for Futility Guideline Consensus

Inhaled Bronchodilators (Salbutamol) Pathophysiology is mechanical epithelial plugging and edema, not smooth muscle constriction. Multicenter trials show no improvement in oxygenation, admission rate, or hospital stay. Triggers tachycardia, tremors, and paradoxically worsens V/Q mismatch by vasodilation in non-ventilated lung units. Do not use routinely for bronchiolitis (AAP, NICE, EAP)

Systemic Corticosteroids (Dexamethasone, Prednisolone) Corticosteroids do not reduce viral replication, inflammatory edema, hospital admission rates, or length of stay. Adverse effects include immunosuppression, hypertension, and hyperglycemia. Do not use for routine bronchiolitis treatment

Nebulized Adrenaline May provide brief, transient physiological improvement (alpha-1 vasoconstriction) during the first hour, but large multicenter trials show zero sustained clinical benefit or reduction in hospital stay. Not Recommended for routine use

Nebulized Hypertonic Saline (3%) While hypothesized to rehydrate periciliary liquid and break mucus bonds, large modern RCTs show no clinically meaningful reduction in hospital duration or PICU transfer rates. Not Recommended in acute emergency protocols

Antibiotics (Oral or IV) Bronchiolitis is an exclusively viral condition. Secondary bacterial pneumonia occurs in <1% to 2% of cases. Indiscriminate antibiotic prescribing drives microbial resistance and disrupts developing microbiome. Do not use routinely ; treat proven or strongly suspected concurrent bacterial infection without waiting for culture confirmation

Chest Physiotherapy Routine percussion/vibration does not improve the clinical course and may distress the infant. Not routine ; consider assessment for secretion-clearance problems with relevant comorbidities, such as spinal muscular atrophy or severe tracheomalacia

Routine Chest X-rays Routine CXRs show peribronchial thickening and patchy atelectasis, which are routinely misread as "bacterial consolidation," driving inappropriate antibiotic prescribing. Not routine ; consider if intensive care is proposed, deterioration is unexpected or an alternative diagnosis is suspected

Tip

The most powerful intervention in acute bronchiolitis is de-escalation : stopping useless bronchodilators, avoiding unnecessary antibiotics, withholding futile steroids, minimizing handling, and providing targeted hydration. Consider superficial nasal suction when upper-airway secretions impair feeding or breathing; do not suction routinely.

Discharge Criteria and Parental Safety-Netting

An infant hospitalized with bronchiolitis is clinically ready for discharge when all of the following criteria are fulfilled:

Hemodynamic and Respiratory Stability: Clinically stable with a respiratory rate <60 breaths/min and no significant work of breathing (absence of grunting, nasal flaring, or severe intercostal retractions).

Adequate Oxygenation: In room air for 4 hours including sleep , maintain SpO2 over 90% at age ≥6 weeks , or over 92% below 6 weeks or with an underlying health condition (NICE).

Adequate Enteral Intake: Consuming at least 60% to 75% of normal fluid requirements orally without fatigue, choking, or vomiting.

Social and Caregiver Readiness: Caregivers are confident in assessing the infant's work of breathing, understand feeding support, and have access to emergency services.

Explicit Red Flag Safety-Netting: Seek immediate medical help for apnoea, cyanosis, worsening work of breathing (grunting, marked chest recession or RR >70/min), exhaustion, intake falling to 50–75% of normal, or no wet nappy for 12 hours .

  • Prevention: Monoclonal Antibody Immunoprophylaxis
  • Nirsevimab: Universal Infant Protection

Pharmacology: A recombinant human IgG1κ long-acting monoclonal antibody that binds specifically to the highly conserved antigenic site Ø on the prefusion (pre-F) conformation of the RSV F glycoprotein, neutralizing viral entry.

Modified Fc Domain: Engineered with a triple amino acid substitution (M252Y/S254T/T256E [YTE]) in the Fc region that dramatically extends its serum elimination half-life to 60 to 80 days .

Clinical Administration: Administered as a single intramuscular injection that confers sustained protection against lower respiratory tract infection for at least 5 months , covering the entire typical European winter RSV season.

Dose: 50 mg IM for infants weighing <5 kg; 100 mg IM for infants weighing ≥5 kg.

European Indication: Approved and widely adopted across European national immunization programs for all neonates and infants entering or born during their first RSV season , reducing RSV-associated hospitalizations by >80% .

Palivizumab: Targeted High-Risk Protection

Pharmacology: Humanized murine monoclonal antibody targeting antigenic site II of the RSV F glycoprotein.

Regimen: Requires monthly intramuscular injections of 15 mg/kg (up to 5 monthly doses throughout the RSV season).

Contemporary Role: Historically the primary prophylactic agent; largely superseded by nirsevimab because of its single-dose convenience and longer duration of action, but remains an alternative for select infants with chronic lung disease of prematurity (BPD) or hemodynamically significant congenital heart disease where national programs dictate.